Clinical Trial Update: MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis

View source ↗

Summary

The clinical trial evaluating monitoring of MPA AUC in MMF-treated systemic sclerosis patients with diffuse cutaneous or pulmonary involvement has been terminat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Systemic Sclerosis | Status: TERMINATED